中国创新药进入“深水区”,供应链如何从“赋能”到“共谋”?

21世纪经济报道
Mar 16

21世纪经济报道记者季媛媛  当中国创新药管线占据全球30%的份额,当中国不再是仅仅承接海外授权,而是成为全球大型药企引进资产的重要策源地,整个产业生态的供需关系正在发生微妙的位移。  在刚刚落幕的第十一届易贸生物产业大会(BioChina 2026)上,这一变化表现得尤为明显。过去,跨国巨头们在中国的叙事往往是“将全球创新带入中国”。而今天,上游供应商开始反复强调“中国需要,我们做到”。  ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10